Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity

  • Codiak BioSciences Inc CDAK announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. 
  • In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety and tolerability profile, with no detectable systemic exposure of IL-12 and no treatment-related adverse events. 
  • The two patients with cutaneous T cell lymphoma who have been treated each received multiple injections of exoIL-12 and experienced tumor regressions in both injected and non-injected lesions, including a partial response in one patient. 
  • Read Next: Codiak BioSciences's Pan Beta-Coronavirus Vaccine Shows Encouraging Action In Animal Studies.
  • In the Phase 1/2 trial of exoSTING in late-stage refractory solid tumors, data across all five dose cohorts showed that repeat doses of exoSTING were well-tolerated and demonstrated tumor retention with no systemic exposure of the STING agonist.
  • In a subset of patients, tumor shrinkage was observed in injected and uninjected lesions.  
  • Price Action: CDAK shares traded lower by 16.2% at $3.05 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!